Joseph Papa compensation by year
Emergent BioSolutions Summary Compensation Table · all 2 fiscal years held| Component | FY2024 | FY2025 |
|---|---|---|
| Salary | $800,000 | $1,037,385 |
| Bonus | $1,000,000 | $0 |
| Stock awards | $516,000 | $1,638,500 |
| Option awards | $1,973,050 | $1,191,500 |
| Non-equity incentive | $1,566,474 | $1,446,640 |
| Pension and deferred compensation | — | $0 |
| All other | $7,038 | $7,122 |
| Total | $5,862,562 | $5,321,147 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Emergent BioSolutions Inc. DEF 14A filed March 20, 2026, accession 0001367644-26-000033, and prior-year filings.
How this page was built: the Emergent BioSolutions Inc. filed document, accession 0001367644-26-000033. Every figure is read from that document and cited to the page and table it appears in. Filed March 20, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 533,333 | $6,591,996 | — |
| RSU | 282,500 | $3,491,700 | — |
| Option | 333,500 | — | $2.33 |
| Option | 166,750 | — | $2.33 |
| Option | 250,000 | — | $2.33 |
| Option | 282,500 | — | $5.80 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Emergent BioSolutions Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
1 Form 4 line since the FY2025 proxy (filed March 20, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-04-29 | Grant or award | — | 187,708 | $0.00 | 493,153 |
The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Emergent BioSolutions discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $3,588,000 | $7,519,993 | $50,061 | $11,158,054 |
| Change in control and involuntary termination | $5,980,000 | $17,882,400 | $83,435 | $23,945,835 |
Per the Potential Payments Upon Termination or Change in Control table in Emergent BioSolutions Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Emergent BioSolutions’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Joseph Papa · this page | President, Chief Executive Officer and Director | $5,321,147 |
| Richard Lindahl | Executive Vice President, Chief Financial Officer | $2,708,723 |
| Coleen Glessner | Executive Vice President, Quality and Ethics and Compliance | $1,664,258 |
| Simon Lowry | Chief Medical Officer, Head of Research and Development | $1,471,276 |
| Paul Williams | Senior Vice President, Products Business | $1,391,158 |
Board service
Emergent BioSolutions board · FY2023–FY2025How this board is paid
Company policy: Emergent BioSolutions pays directors a $70,000 cash retainer and $250,000 in 75% RSUs and 25% stock options. As stated in Emergent BioSolutions's FY2025 proxy.
The full Emergent BioSolutions compensation record
free company briefThis page is one person within Emergent BioSolutions's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Emergent BioSolutions proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Emergent BioSolutions's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Emergent BioSolutions's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.